Beta Drugs Limited has informed the Exchange regarding Proceedings of Extraordinary General Meeting held on February 04, 2026
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited has submitted to NSE the proceedings (outcome/result) of its Extraordinary General Meeting (EGM) held on February 4, 2026. This is a routine compliance filing under SEBI listing regulations, in which the company discloses the resolutions that were placed before shareholders and whether they were passed. The exact nature of the resolutions (such as fund raising, preferential allotment, capital changes, or amendments to articles) is not specified in the available text. Investors should check the full outcome document for details on voting results and the items approved.
This is primarily a procedural disclosure and is unlikely to move the stock on its own, but the actual resolutions passed at the EGM (if they involve fundraising, dilution, or major strategic changes) could have a meaningful effect on shareholders.